X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10472) 10472
Book Review (1290) 1290
Newsletter (1057) 1057
Newspaper Article (930) 930
Publication (849) 849
Book Chapter (39) 39
Conference Proceeding (36) 36
Trade Publication Article (20) 20
Magazine Article (16) 16
Book / eBook (14) 14
Dissertation (14) 14
Web Resource (8) 8
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8878) 8878
humans (7951) 7951
neuroblastoma (7616) 7616
oncology (3602) 3602
animals (3243) 3243
neuroblastoma - drug therapy (3173) 3173
cancer (3040) 3040
cell line, tumor (2769) 2769
neuroblastoma - pathology (2581) 2581
female (2433) 2433
apoptosis (2359) 2359
male (2341) 2341
mice (2057) 2057
child (1900) 1900
child, preschool (1645) 1645
research (1643) 1643
neuroblastoma - metabolism (1603) 1603
tumors (1601) 1601
pediatrics (1541) 1541
chemotherapy (1470) 1470
infant (1381) 1381
apoptosis - drug effects (1266) 1266
expression (1265) 1265
neurosciences (1125) 1125
biochemistry & molecular biology (1113) 1113
proteins (1087) 1087
neuroblastoma - genetics (1027) 1027
cell biology (1015) 1015
care and treatment (1014) 1014
adolescent (915) 915
tumor cells, cultured (905) 905
antineoplastic agents - pharmacology (893) 893
analysis (886) 886
cell survival - drug effects (886) 886
children (871) 871
pharmacology & pharmacy (865) 865
gene expression (863) 863
cancer therapies (852) 852
health aspects (826) 826
dose-response relationship, drug (794) 794
prognosis (784) 784
oxidative stress (778) 778
neuroblastoma - therapy (750) 750
antineoplastic combined chemotherapy protocols - therapeutic use (724) 724
neuroblastoma-cells (691) 691
therapy (690) 690
drugs (683) 683
antineoplastic agents - therapeutic use (671) 671
medicine (653) 653
article (651) 651
cell proliferation - drug effects (638) 638
rats (634) 634
kinases (632) 632
adult (619) 619
hematology (616) 616
in-vitro (615) 615
cells (605) 605
genetic aspects (605) 605
metastasis (599) 599
research article (583) 583
medical research (578) 578
activation (552) 552
cytotoxicity (551) 551
differentiation (546) 546
treatment outcome (543) 543
immunotherapy (541) 541
growth (534) 534
multidisciplinary sciences (528) 528
signal transduction (514) 514
reports (511) 511
neurons (504) 504
combined modality therapy (502) 502
mice, nude (501) 501
cell cycle (498) 498
drug therapy (489) 489
neurons - drug effects (484) 484
biology (482) 482
inhibition (479) 479
surgery (479) 479
time factors (479) 479
neoplasms - drug therapy (474) 474
cell line (465) 465
in-vivo (465) 465
phosphorylation (460) 460
signal transduction - drug effects (456) 456
neuroblastoma cells (454) 454
mutation (449) 449
science (447) 447
physiological aspects (442) 442
alzheimers-disease (436) 436
blotting, western (436) 436
cell death (432) 432
high-risk neuroblastoma (429) 429
toxicity (429) 429
xenograft model antitumor assays (424) 424
abridged index medicus (423) 423
studies (420) 420
brain (418) 418
cell proliferation (418) 418
alzheimer's disease (413) 413
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12224) 12224
German (79) 79
French (68) 68
Japanese (57) 57
Italian (28) 28
Chinese (21) 21
Russian (20) 20
Spanish (18) 18
Polish (17) 17
Dutch (5) 5
Danish (3) 3
Swedish (3) 3
Turkish (3) 3
Hungarian (2) 2
Croatian (1) 1
Czech (1) 1
Finnish (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Biomedical Optics, ISSN 1083-3668, 02/2012, Volume 17, Issue 1, pp. 016014 - 016019
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2010, Volume 363, Issue 14, pp. 1324 - 1334
Journal Article
Drugs, ISSN 0012-6667, 06/2017, Volume 77, Issue 9, pp. 1029 - 1034
Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treatment of... 
THERAPY | HUMAN LUNG | MK-4827 | POLYMERASE INHIBITOR | PHARMACOLOGY & PHARMACY | TOXICOLOGY | CANCER | RADIATION | United States | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Drug Approval | Indazoles - administration & dosage | Peritoneal Neoplasms - drug therapy | Piperidines - pharmacology | Adult | Female | Maintenance Chemotherapy | Ovarian Neoplasms - drug therapy | United States Food and Drug Administration | Fallopian Tube Neoplasms - drug therapy | Piperidines - administration & dosage | Double-Blind Method | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Randomized Controlled Trials as Topic | Indazoles - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Piperidines - therapeutic use | Piperidines - adverse effects | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indazoles - adverse effects | Indazoles - therapeutic use | Drug therapy | Ovarian cancer | Ovarian carcinoma | Homology | Metastasis | Neuroblastoma | Fallopian tube | ADP | Cancer therapies | DNA repair | Ribose | Platinum | Cell cycle | Drug dosages | Deoxyribonucleic acid--DNA | Recombinant | Enzymes | Poly(ADP-ribose) polymerase | Breast cancer | Maintenance | Radiation therapy | Patients | Studies | Polymerase | Chemotherapy | Mutation | Solid tumors | Prostate cancer | Prostate | Tumors | Cancer | Apoptosis | Peritoneum | Index Medicus
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 04/2003, Volume 95, Issue 7, pp. 516 - 525
Hypoxia-inducible factor 1 alpha (HIF-1alpha), a component of HIF-1, is expressed in human tumors and renders cells able to survive and grow under hypoxic... 
Intercellular Signaling Peptides and Proteins - analysis | Neoplasms - metabolism | Vascular Endothelial Growth Factor A | G(M1) Ganglioside - analysis | Vascular Endothelial Growth Factors | Humans | Immunoblotting | Male | Transplantation, Heterologous | Hypoxia-Inducible Factor 1, alpha Subunit | Transcription Factors - drug effects | Endothelial Growth Factors - analysis | Carcinoma, Hepatocellular - drug therapy | Female | Neovascularization, Pathologic - prevention & control | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Tumor Cells, Cultured | Carcinoma - drug therapy | Cell Hypoxia - drug effects | Enzyme-Linked Immunosorbent Assay | Liver Neoplasms - drug therapy | Angiogenesis Inhibitors - pharmacology | Platelet Endothelial Cell Adhesion Molecule-1 - analysis | Rats | Neoplasms - blood supply | Uterine Cervical Neoplasms - drug therapy | Stomach Neoplasms - drug therapy | Mice, SCID | Reverse Transcriptase Polymerase Chain Reaction | Precipitin Tests | Neoplasms - drug therapy | Indazoles - pharmacology | Transcription Factors - metabolism | Culture Media, Conditioned | Animals | Lymphokines - analysis | Neuroblastoma - drug therapy | Killer Cells, Natural - drug effects | Mice | Neovascularization, Pathologic - metabolism | Killer Cells, Natural - metabolism | Kidney Neoplasms - drug therapy | Antimitotic agents | Antineoplastic agents | Evaluation | Drug therapy | Medical treatment | Cancer | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 67, pp. 130 - 140
Abstract Objectives Dose-finding trials are fundamental to develop novel drugs for children and adolescents with advanced cancer. It is crucial to maximise... 
Hematology, Oncology and Palliative Medicine | Innovative Therapies for Children with Cancer | Dose-finding trial | Prognostic factor | Phase I trial | Children | Adolescents | Survival | ONCOLOGY TRIALS | SCORE | VALIDATION | I CLINICAL-TRIALS | CONTEXT | PEDIATRIC PHASE-I | CENTER EXPERIENCE | ONCOLOGY | Osteosarcoma - drug therapy | Multivariate Analysis | Prognosis | Neuroectodermal Tumors, Primitive - drug therapy | Humans | Child, Preschool | Infant | Male | Neuroblastoma - mortality | Sarcoma, Ewing - mortality | Medulloblastoma - mortality | Ependymoma - drug therapy | Employment | Ependymoma - mortality | Sarcoma - mortality | Female | Rhabdomyosarcoma - drug therapy | Retrospective Studies | Child | Rhabdomyosarcoma - mortality | Schools | Osteosarcoma - mortality | Glioma - mortality | Neuroectodermal Tumors, Primitive - mortality | Europe | Proportional Hazards Models | Neoplasms - mortality | Therapies, Investigational | Survival Rate | Sarcoma - drug therapy | Neoplasms - drug therapy | Sarcoma, Ewing - drug therapy | Neuroblastoma - drug therapy | Adolescent | Medulloblastoma - drug therapy | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Clinical Trials, Phase I as Topic | Glioma - drug therapy | Care and treatment | Patient outcomes | Children's hospitals | Oncology, Experimental | Clinical trials | Research | Health aspects | Cancer | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 18, pp. 4133 - 4141
Journal Article
Journal Article
Cancer Cell, ISSN 1535-6108, 11/2014, Volume 26, Issue 5, pp. 682 - 694
Journal Article
Cancer Research, ISSN 0008-5472, 05/2008, Volume 68, Issue 9, pp. 3389 - 3395
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2012, Volume 7, Issue 5, pp. e38129 - e38129
Journal Article
Cancer Discovery, ISSN 2159-8274, 11/2015, Volume 5, Issue 11, pp. 1210 - 1223
Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic agent can facilitate the development of precision cancer... 
ACTIVATION | ONCOLOGY | CANCER DRUG-RESISTANCE | KINASE | ALK MUTATIONS | RECEPTOR | KRAS | NEUROBLASTOMA | INHIBITOR | IDENTIFICATION | EXPRESSION